Unraveling the microbiome-metabolome nexus: a comprehensive study protocol for personalized management of Behçet's disease using explainable artificial intelligence

Front Microbiol. 2024 Feb 12:15:1341152. doi: 10.3389/fmicb.2024.1341152. eCollection 2024.

Abstract

The presented study protocol outlines a comprehensive investigation into the interplay among the human microbiota, volatilome, and disease biomarkers, with a specific focus on Behçet's disease (BD) using methods based on explainable artificial intelligence. The protocol is structured in three phases. During the initial three-month clinical study, participants will be divided into control and experimental groups. The experimental groups will receive a soluble fiber-based dietary supplement alongside standard therapy. Data collection will encompass oral and fecal microbiota, breath samples, clinical characteristics, laboratory parameters, and dietary habits. The subsequent biological data analysis will involve gas chromatography, mass spectrometry, and metagenetic analysis to examine the volatilome and microbiota composition of salivary and fecal samples. Additionally, chemical characterization of breath samples will be performed. The third phase introduces Explainable Artificial Intelligence (XAI) for the analysis of the collected data. This novel approach aims to evaluate eubiosis and dysbiosis conditions, identify markers associated with BD, dietary habits, and the supplement. Primary objectives include establishing correlations between microbiota, volatilome, phenotypic BD characteristics, and identifying patient groups with shared features. The study aims to identify taxonomic units and metabolic markers predicting clinical outcomes, assess the supplement's impact, and investigate the relationship between dietary habits and patient outcomes. This protocol contributes to understanding the microbiome's role in health and disease and pioneers an XAI-driven approach for personalized BD management. With 70 recruited BD patients, XAI algorithms will analyze multi-modal clinical data, potentially revolutionizing BD management and paving the way for improved patient outcomes.

Keywords: Behçet’s disease; autoinflammatory disease; butyrate; explainable artificial intelligence; gut; innate immunity; microbiome; volatilome.

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was funded by the University of Bari, Poject XAI4Microbiome – Intelligenza Artificiale eXplainable per l’identificazione di marker metabolici personalizzati nella malattia di Behçet, code S30 – CUP H99J21017720005. The National Recovery and Resilience Plan (NRRP), Mission 4 Component 2 Investment 1.4—Call for tender No. 3138 of 16 December 2021 of Italian Ministry of University and Research funded by the European Union—NextGenerationEU. Award Number: Project code: CN00000013, Concession Decree No. 1031 of 17 February 2022 adopted by the Italian Ministry of University and Research, CUP H93C22000450007, Project title: “National Centre for HPC, Big Data and Quantum Computing” support partially this project.